Evaluation of Effectiveness and Safety of NOBORI Stent in Routine Clinical Practice; A Multicenter, Prospective, Observational Study.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Umirolimus (Primary) ; Paclitaxel; Sirolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-NOBORI
- 10 Jun 2017 Biomarkers information updated
- 14 Sep 2015 Planned End Date changed from 1 Dec 2016 to 1 Apr 2020, as reported by ClinicalTrials.gov.
- 14 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.